Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis
Recruiting
Observational Study
Autoimmune Pancreatitis
IgG4-Related Diseases
Pancreatic Cancer
Chronic Pancreatitis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 82 (estimated)
- Sponsor
- Military Medical Clinical Center of the Southern Region, Ukraine · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This ambispective observational study aims to validate the Odesa Criteria 2026 (OC26), a flexible domain-based point scoring system for diagnosing autoimmune pancreatitis. The study evaluates diagnostic accuracy and reproducibility of OC26 across clinical, serological, morphological, and histological domains.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults (≥18 years) undergoing evaluation for suspected autoimmune pancreatitis.
* Availability of clinical, serological, imaging, and/or histological data required for OC26 scoring.
* Ability to provide informed consent (for prospective participants).
Exclusion Criteria:
* C…
Contacts